Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALA-4000
- Development stage
- Preclinical
- Lead developer
- Alar Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intramuscular, Intranasal, Intravenous, Subcutaneous, Sublingual
01
Overview
ALA-4000 is a long-acting, sustained-release injectable formulation of apomorphine being developed by Alar Pharmaceuticals for the treatment of Parkinson's disease. Apomorphine is a non-ergoline dopamine agonist that acts on D1-like and D2-like receptors. The ALA-4000 formulation is designed to provide continuous dopaminergic stimulation, potentially reducing the "off" periods and motor fluctuations associated with standard levodopa therapy while minimizing the side effects and administration burden of current apomorphine delivery methods, such as frequent subcutaneous injections or continuous infusion pumps. It is currently in the pre-clinical stage of development.
- Other names
- sustained-release apomorphine
02
Targets
DRD4 (Dopamine D4 Receptor)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD5 (Dopamine D5 Receptor)
Beyond the preview
Go deeper on ALA-4000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALA-4000.